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Type 1 diabetes (T1D) and type 2 diabetes (T2D) are multifactorial diseases with different
etiologies in which chronic inflammation takes place. Defects in invariant natural killer
T (iNKT) cell populations have been reported in both T1D and T2D patients, mouse
models and our recent study revealed mucosal-associated invariant T (MAIT) cell defects
in T2D and obese patients. Regarding iNKT cells many studies in non-obese diabetic
mice demonstrated their protective role against T1D whereas their potential role in human
T1D is still under debate. Studies in mouse models and patients suggest that iNKT cells
present in adipose tissue (AT) could exert a regulatory role against obesity and associated
metabolic disorders, such as T2D. Scarce data are yet available on MAIT cells; however,
we recently described MAIT cell abnormalities in the blood and ATs from obese and T2D
patients. These data show that a link between MAIT cells and metabolic disorders pave
the way for further investigations on MAIT cells in T1D and T2D in humans and mouse
models. Furthermore, we hypothesize that the gut microbiota alterations associated with
T1D and T2D could modulate iNKT and MAIT cell frequency and functions. The potential
role of iNKT and MAIT cells in the regulation of metabolic pathways and their cross-talk
with microbiota represent exciting new lines of research.
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Introduction
According to the WHO diabetes will be in 2030 the seventh leading cause of death (1). Type 1
diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of the insulin-
producing pancreatic β-cells, resulting in insulin deficiency and hyperglycemia. Type 2 diabetes
(T2D) that accounts for 90–95% of all cases of diabetes, is characterized by insulin resistance,
hyperglycemia, and decreased β-cell function and mass. The immune system is known to play a
deleterious role in T1D as evidenced already in 1965 by Gepts who described insulitis in patients
with T1D (2). More recent studies have shown that insulitis also occurs in patients with T2D, and
support the notion that inflammation may participate in the pathogenesis of T2D (3, 4).
Invariant natural killer T (iNKT) andmucosal-associated invariant T (MAIT) cells are evolution-
ary conserved T cell subsets. iNKT and MAIT cells express semi-invariant T cell receptor (TCR) α
chains: Vα24Jα18 and Vα7.2Jα33 in humans (Vα14Jα18 and Vα19Jα33 in mice), respectively (5,
6). Both display a memory phenotype, can readily produce cytokines, and thus, represent a bridge
between innate and adaptive immunity. Based on mouse models, iNKT cells exert a regulatory role
in T1D, while their role in T2D is still matter of debate. RegardingMAIT cells and diabetes, virtually
nothing is known and the first insights regarding MAIT cells in T2D patients (7) have only recently
been published.
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Genetic and environmental factors are crucial in the devel-
opment of T1D and T2D with growing evidence supporting an
important role of the gut microbiota. This review will focus on
iNKT and MAIT cells in the context of diabetes and discuss the
potential impact of altered gut microbiota on these immune cells.
iNKT Cell Defects in Non-Obese Diabetic
Mice
The implication of iNKT cells in diabetes was first demonstrated
in non-obese diabetic (NOD) mice that spontaneously develop
T1D. Numerical and functional iNKT cell defects in NOD mice
have been identified: reduced iNKT cell frequency and IL-4 pro-
duction (8, 9). When compared with 37 other inbred mouse
strains, in NODmice iNKT cell numbers are at the low end of the
spectrum in different tissues (i.e., peripheral blood, spleen, and
thymus) (10). In NODmice, defects in the expression of SLAM by
double positive thymocytes that are responsible for the positive
selection of NKT cells (11) and by myeloid dendritic cells (DCs)
(12) are sought to play a role in the reduced iNKT cell number and
impaired iNKT cell IL-4 production, respectively. Several other
locimodulating iNKT cells inNODmice have been identified (13,
14).More recently, Tsaih and colleagues demonstrated that a locus
in chromosome 13 inversely regulates CD1d expression on double
positive thymocytes and iNKT cell frequency, with the NOD allele
shown to promote high CD1d expression on thymocytes and
subsequent low iNKT cell frequency (15).
Of note, NODmice have elevated frequency and number of an
iNKT cell subpopulation producing IL-17, namely, iNKT17 cells,
in the thymus and periphery (16). In the pancreatic lymph nodes,
iNKT17 cells represent 13% of total iNKT cells in NOD mice as
compared to 2% in C57BL/6 mice (16, 17).
Regulatory Role of iNKT Cells in T1D in
Mice
The accelerated development of T1D in CD1d-deficient NOD
mice (18, 19), and the prevention of T1D development in NOD
mice with increased iNKT cell number (20, 21) have suggested
that iNKT cells play overall a protective role in T1D. T1D protec-
tion mediated by iNKT cells after cell transfer, upon cyclophos-
phamide treatment, or activation by α-galactosylceramide (α-
GalCer), was shown to rely on IL-4 and/or IL-10 production
(20, 22) and inhibition of pathogenic autoimmune responses (23,
24). Repetitive stimulation with α-GalCer-induced tolerogenic
myeloid DCs (25) and plasmacytoid DCs that in turn converted
naive BDC2.5 diabetogenic T cells into regulatory T (Treg) cells
in pancreatic lymph nodes (26). Our group also demonstrated
that iNKT cells could induce BDC2.5 T cell anergy in a cytokine-
independent (i.e., IL-4, IL-10, IL-13, and TGF-β) (27) fashion, but
required cell–cell contact and was independent of CD1d expres-
sion in the periphery, suggesting that molecular interactions other
than CD1d/TCR are involved (28).
Environmental factors, such as viral infections, can be either
deleterious or protective in T1D. Upon lymphochoriomeningitis
virus infection, in pancreatic lymph nodes iNKT cells-induced
tolerogenic plasmacytoid DCs, which converted naive T cells into
Treg cells that migrated to the pancreatic islets and inhibited
anti-islet T cells, thereby providing protection against T1D (29).
Of note, even though a single injection of α-GalCer at the time
of infection increased the frequency of Treg cells in pancreatic
islets, and further promoted the protection against T1D, such
protection was even seen in the absence of α-GalCer injection in
wild type mice, but not in CD1d and Jα18 deficient NOD mice.
Thus, iNKT cells are key in the induction of Treg cells and the
protection against T1D in this infectious setting. We have also
analyzed the role of iNKT cells upon another viral infection that
is relevant to the human disease. Coxsackievirus B4 has been pro-
posed as an etiologic agent that could promote the development
of T1D in patients as well as in the diabetes susceptible NOD
mouse. Coxsackievirus B4 infection accelerated T1D in NOD
mice, whereas α-GalCer injection at the time of infection acti-
vated pancreatic iNKT cells that produced rapidly large amount
of IFN-γ and upregulated indoleamine 2,3-dioxygenase produc-
tion by macrophages recruited in the pancreas. These suppressive
macrophages inhibited pancreatic anti-islet T cells and subse-
quently prevented T1D development (30). These data together
showed that in both viral infections, through two different mech-
anisms, iNKT cells exert an efficient regulatory role.
However, not all iNKT cell subsets are protective. We showed
that iNKT17 cells infiltrate the pancreas of NOD mice and pro-
mote diabetes development. α-GalCer treatment suppresses IL-17
(and to a lesser extend IFN-γ) produced by iNKT cells, which
could also contribute to the protective role of α-GalCer in T1D
(16). Of note, the presence of IL-1 and IL-6 in inflamed pancreatic
islets of NOD mice may contribute to the activation of iNKT17
cells (31).
Putative Role of iNKT Cells in Human T1D
The first data obtained in patients with T1D showed a decreased
frequency of iNKT cells as well as a defect in IL-4 production
(32) but since, contradictory results from clinical studies have
been published; some following reports have supported this find-
ing (33, 34), while one report has shown increased numbers of
iNKT cells (35), and others did not find differences in iNKT cell
numbers (36–39).
While the frequency of iNKT17 cells might be extremely low
in the peripheral blood of healthy controls and patients with T1D,
iNKT17 cells could be expanded in vitro in the presence of IL-1β.
These cells were only obtained from the blood of T1D patients but
not from healthy controls (40), suggesting that iNKT17 cells could
also be involved in T1D pathogenesis in patients.
Altogether, despite converging evidence that iNKT cells play a
regulatory role in T1D using mouse models, their role in human
T1D remains controversial urging more clinical studies with well
defined T1D patient cohorts.
iNKT Cells in T2D and Obesity
Type 2 diabetes is a progressive disease resulting from the insulin
resistance that develops with advancing age and lifestyle factors,
such as inactivity, diet, and obesity (most patients with T2D are
obese or overweight), but those factors are not the only trigger. It
is now recognized that T2D results from the interaction between
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different genetic events and with environmental factors (41). The
detection of TNF-α in obese rat adipose tissue (AT) provided the
first evidence that tissue inflammation was correlated with insulin
resistance andT2D (42). In the lean stateM2macrophages with an
anti-inflammatory phenotype accumulate in AT, whereas obesity
leads to the preferential accumulation in AT of proinflammatory
M1macrophages known to participate in insulin resistance devel-
opment. Other immune cells infiltrate AT, and iNKT cells are
particularly enriched in white AT.
In obese mice, iNKT cell frequency in white AT is decreased
while weight loss reverses decreased AT iNKT cell frequency
(43). Several studies have analyzed the impact of iNKT cells in
metabolic control with contradictory results. The use of CD1d / 
or Jα18 /  mice lacking all NKT cells (iNKT and variant NKT
cells) or only iNKT cells, respectively, and other factors, such as
different diets, or experimental procedures have been implicated
to explain the protective, the absence, or the negative impact
of iNKT cells on weight gain or metabolic control (44, 45). In
a recent review, Lynch argues that despite the divergent results
obtained using iNKT-deficient mouse models, most experiments
using transferred or activated α-GalCer iNKT cells converge to
support a protective role of iNKT cells in obesity and she pro-
poses that AT iNKT cells via IL-4 and IL-10 production reg-
ulate anti-inflammatory cytokines and adipocyte function (46).
The regulatory role of AT iNKT cells is supported by recent
findings showing that in murine AT, iNKT cells did not express
the PLZF transcription factor, characteristic of iNKT cells, but
instead the transcription factor E4BP4, and via IL-10 and IL-2
expression control the homeostasis ofmacrophages and Treg cells,
respectively (47).
In obese patients as compared to lean individuals, iNKT cell
frequency is decreased in omentalAT andperipheral blood (7, 48).
Conversely, iNKT cell frequency in peripheral blood is restored
after bariatric surgery of obese patients (43).
MAIT Cells in T1D
Due to the lack of specific antibodies directed against the murine
Vα19TCR chain, limited data onmurineMAIT cells are available.
However, the recent development of mouse MR1-antigen loaded
tetramers detecting specifically MAIT cells (49) will most likely
soon shed a new light on the role ofMAIT cells in different mouse
disease models, such as diabetes.
To date, only scarce data on the role of MAIT/MAIT-like cells
in T1D are available. The observation that the expression of
Vα19Jα33 TCR as a transgene in NOD mice delays the onset of
T1D (50) suggests that MAIT cells may play a protective role. In
humans, MAIT cells are identified using anti-Vα7.2 TCR chain
and anti-CD161 antibodies. A recent report analyzed that the
CD161brightCD8+ T cell subset in juvenile T1D patients (51),
with the CD161brightCD8+ T cells displaying a phenotype, IL-
18Rα+, CD127+, CD45RA , and CCR7 , suggestive of MAIT
cells. No difference in the CD161brightCD8+ T cell frequency was
observed in juvenile T1D patients as compared to age-matched
controls. As described previously for MAIT cells (52), the fre-
quency of CD161brightCD8+ T cells increased with age in juve-
nile controls and new-onset T1D patients but not in juvenile
long-standing (1 year) T1D patients. These results suggest that
in long-standing T1D patients the circulating CD161brightCD8+
T cells may be depleted. The CD27  CD161brightCD8+ T cells
(a subset enriched in IL-17 producing cells) were increased in
patients with T1D as compared to controls. Further studies of T1D
patients using anti-Vα7.2 TCR chain and anti-CD161 antibodies
and/or with human MR1-antigen loaded tetramers specifically
directed toward MAIT cells are needed in order to accurately
decipher their role in T1D.
Additionally, whether MAIT cells as seen for IL-17-producing
γδ T cells exit the thymus as CD27  cells (53), or acquire the
CD27  phenotype in the periphery upon activation and differ-
entiation as observed for Th17 cells (54) and the understanding
of the underlying mechanisms would be of utter interest.
MAIT Cell Defects in T2D and Obese
Patients
Our group has shown that MAIT cells exhibit several defects in
T2D and obese patients (7).MAIT cell frequencywas dramatically
reduced in patientswithT2D, andparticularly in obese patients. In
12/69 severe obese patients study, we could not detect circulating
MAIT cells. Higher frequencies of MAIT cells producing IL-17
were detected in T2D and obese patients, as compared to lean
control individuals, and this was even more pronounced in T2D
patients. Furthermore, when stimulated in vitro with MAIT cell
ligand, a higher frequency ofT2DpatientMAIT cells produced IL-
17.We showed thatMAIT cells are present in the omental and sub-
cutaneous AT, with comparable frequencies between lean control
individuals and obese patients. Interestingly, in five obese patients
for whom we could not detect circulating MAIT cells, MAIT cells
were present in omental AT. In AT, and particularly subcutaneous
AT, a vast majority of MAIT cells from obese patients, but not
from lean control individuals, produced IL-17. AT from obese
patients promoted MAIT cell activation (upregulation of CD25
andCD69 expression), and as compared to circulatingMAIT cells,
AT MAIT cells displayed higher Ki67 expression, altogether sug-
gesting a recruitment, and local activation ofMAIT cells in theAT.
Bariatric surgery of obese patients restored circulating MAIT cell
frequency anddecreased their production of IL-2 and granzymeB.
However, up to 12months post-surgery high frequencies ofMAIT
cells still displayed an augmented Th17 profile. A recent report by
Carolan et al. confirms our observation on MAIT cell alteration
in adult obesity, showing decreased MAIT cell frequency and
increased IL-17 production (55). However, the frequency of circu-
lating MAIT cells in obese children was increased as compared to
lean children, and this increased frequency in patients was associ-
ated with hyperinsulinemia and insulin resistance. Their analysis
of adult obese patients’ AT confirms the increased production of
IL-17 by MAIT cells and shows a decreased frequency of IL-10
producing MAIT cells.
The mechanisms underlying MAIT cells defects and increased
IL-17 production in T2D and obesity remain to elucidate. For
instance, whether the expression of IL-1β (56) and IL-6 (57) in
the AT of T2D patients plays a role in MAIT cell activation and
production would be of interest. Altogether, these data show alter-
ations of the MAIT cell compartment in T2D and obese patients
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and paves the way for further studies assessing the role of MAIT
cells in diabetes and metabolic disorders.
iNKT and MAIT Cells and Impact of
Microbiota in T1D and T2D
Type 1 diabetes and T2D are linked to genetic predisposition but
non-genetically determined factors, such as the gut microbiota,
also impact their development. We will discuss below how altered
gut microbiota may impact iNKT cells and MAIT cells in T1D
and T2D.
Invariant natural killer T and MAIT cells are present in human
andmurine AT and intestine. In mice, microbial exposure early in
life impacts iNKT cell numbers (58), and in germ-freemiceMAIT
cells are absent in peripheral tissues (59). Altogether, these results
show that commensal bacteria impact intestinal iNKT cell home-
ostasis, and are essential for MAIT cell expansion. The microbial
lipids activating intestinal iNKT cells remain to be elucidated, but
recent reports have shown that, in a CD1d-dependent fashion,
some sphingolipids from the gut commensal Bacteroides fragilis
activate (60) while other sphingolipids inhibit iNKT cells (61).
MAIT cell ligands are MR1-restricted derived bacterial products
of vitamin B metabolism (62). The 6-formyl pterin, a folic acid
(vitamin B9) metabolite is a non-activating ligand, while ligands
derived from the riboflavin (vitamin B2) synthesis pathway, such
as ribityllumazines and pyrimidines, activate MAIT cells. Pyrim-
idines that represent the most potent MAIT cell activating lig-
ands are formed from the condensation of an intermediate of
riboflavin synthesis (5-amino-6--ribitylaminouracil) with the
glucose-derived methylglyoxal or glyoxal (63).
Alterations in the gut microbiota of NOD mice have been
shown to be strongly associated with the development of T1D.
This was supported by gut microbiota transfer experiments from
T1D-protected animals into young diabetes-pronemice that upon
transfer showed delayed T1D or protection from T1D (64, 65).
The impact of the human intestinal microbiota on different dis-
eases including T1D development is a field of intensive investi-
gation and cohort studies designed to address its role on T1D
are currently underway (66). Several studies analyzing the fecal
bacteria composition and metagenomic support the association
between changes in intestinal microbiota and risk of T1D (67,
68). Similarly, alterations of the gut microbiota composition have
been reported in obese mice, obese patients, and patients with
T2D (69). In turn, those alterations in microbiota may impact
gut permeability in T1D, obesity, and T2D; increased bacterial
translocation is thought to contribute to the establishment of
AT microbiota (70). Two metagenome studies of T2D patients
and healthy individuals have revealed differences in microbial
FIGURE 1 | Increased activation of MAIT cells in obesity. Obese
patients show a dramatic decrease of circulating MAIT cells correlated
with increased IL-17 production. The modifications of gut microbiota
may contribute to impaired gut integrity and increased MAIT cell
activation. In the adipose tissue of obese patients, the exacerbated
MAIT cell IL-17 production may contribute to the insulin resistance.
Moreover, the decreased Bcl-2 expression, and increased Ki67
expression in adipose tissue as compared to blood suggest that locally
MAIT cells may be activated and undergo cell death by mechanisms yet
to be determined.
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3414
Magalhaes et al. iNKT and MAIT cells in diabetes
functions related to vitamin metabolism (including riboflavin)
(71, 72). Interestingly, in T1D and T2D patients the production
and plasma levels of methylglyoxal are elevated (73).
The gut microbiota plays a crucial role on iNKT andMAIT cell
development, and iNKT and MAIT cells activating and inhibit-
ing microbial-derived antigens have been identified. Therefore,
it is tempting to speculate that in T1D and T2D alterations of
the gut microbiota, and possibly also AT associated microbiota,
impact iNKT and MAIT cells homeostasis in the gut and AT. We
hypothesize that in diabetes and obesity MAIT cells are recruited
to the gut and/or AT therefore depleting the circulating compart-
ments, and in the AT of obese patients the exacerbated IL-17
production by MAIT cells participate to the local inflammation
and insulin resistance (Figure 1).
Invariant natural killer T cells have been shown to influence
the gut microbial colonization (74). It would be very interesting to
assess ifMAIT cells can alsomodulate the gutmicrobiota. A recent
report showed that circulating MAIT cell deficiency observed in
patients with systemic lupus erythematosus (SLE) and patients
with rheumatoid arthritis (RA) was associated with circulating
iNKT cell deficiency in patients with SLE but not in patients
with RA (75). Furthermore, the authors showed that iNKT cell
activation by α-GalCer induces MAIT cell activation. In obese
patients, we did not find a correlation between the decreased
iNKT and MAIT cell frequency (unpublished data).
Gut microbiota dysbiose and defective gut integrity observed
in T1D and T2D could lead to the presence of TLR ligands in the
blood and peripheral tissues, thereby inducing iNKT and MAIT
cell activation indirectly through DC. However, it is interesting
to note that in our recent study in obese and T2D patients, the
alteration observed in iNKT and MAIT cells was not observed
in other T cell populations, such as conventional T cells and γδT
cells. This data suggest that specific iNKT and MAIT cell ligands
could play a key role in their alteration.
Invariant natural killer T and MAIT cells are evolutionary
conserved populations of innate-like T cells supporting an impor-
tant role as a first line of defense against pathogens. The abun-
dance of iNKT and MAIT cells not only in the AT but also
in the liver prompts the question if iNKT and MAIT cells may
engage in a cross-talk and/or in the regulation of metabolic
pathways.
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